The Bullous Pemphigoid Market involves treating a rare autoimmune disease wherein the immune system attacks the skin and mucous membranes resulting in large fluid-filled blisters and vesicles on the skin and mucosal membrane. Bullous Pemphigoid primarily affects the elderly population above the age of 60 and leads to extensive itching and pain. The main treatment modalities involve immunomodulatory medications such as corticosteroids, anti-inflammatory drugs, and immunosuppressive medications to ease symptoms.
The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.
Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. These companies offer a range of treatment options from oral and topical corticosteroids to immunosuppressive therapies. The increasing geriatric population prone to developing bullous pemphigoid coupled with rising awareness regarding the condition is expected to drive the growth of the market. Additionally, advancements in diagnosis facilitated by digital imaging technologies assist in prompt diagnosis and treatment of the condition, thereby improving treatment outcomes.
Key Takeaways
Key players analysis: Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. GlaxoSmithKline leads the market with drugs including Rituximab and Benlysta.
Growing demand: The growing geriatric population accounted for a major share of the bullous pemphigoid patient pool. According to the WHO, the number of people aged 60 years and older is expected to double by 2050. This significantly drives the demand for bullous pemphigoid treatment.
Technological advancement: Advancements in digital imaging and teledermatology allow accurate diagnosis of bullous pemphigoid through visualization of skin lesions via smartphones and teleconsultation. This enables early intervention and superior management of the condition.
Market Trends
Combination therapies: There is a growing trend of using drug combinations as opposed to monotherapies to effectively manage bullous pemphigoid. Popular combinations involve corticosteroids with immunosuppressants.
Targeted biologic agents: Novel targeted biologic agents aimed at specific antibodies and immune pathways involved in bullous pemphigoid show promise. Drugs like Rituximab, Inebilizumab, and Eculizumab are being evaluated for efficacy and safety.
Market Opportunities
Emerging economies: Countries in Asia Pacific and Latin America present lucrative opportunities for bullous pemphigoid treatment providers owing to growing medical needs of their aging population and economic expansion.
Online consultations: Telehealth and e-pharmacy platforms allow people to remotely access bullous pemphigoid specialists and medication, thereby overcoming distance barriers. This increases access to care.
Impact Of COVID-19 On Bullous Pemphigoid Market Growth
The COVID-19 pandemic has significantly impacted the growth of the bullous pemphigoid market. During the initial phases of the pandemic between 2020-21, the market witnessed a decline in growth rate owing to lockdowns imposed across various countries. This led to postponement of non-essential dermatological procedures and treatments. Patients also avoided visiting healthcare facilities fearing exposure to the virus. As a result, diagnosis and treatment rates for bullous pemphigoid reduced considerably during this period.
However, with lifting of lockdowns and rollout of vaccination drives globally, the market has started recovering post 2021. Increased awareness about the autoimmune disorder and availability of effective treatment options are supporting the growth trajectory. Various initiatives undertaken by key market players to ensure uninterrupted supply of drugs and therapies have also boosted market revenues. For instance, companies streamlined their production and distribution channels to meet the rising demand. Teleconsultations further aided continued care for patients during lockdowns.
Going forward, the bullous pemphigoid market is expected to witness robust expansion supported by ageing population prone to developing the condition. Moreover, rapid advancements in biologics and targeted therapies will expand treatment options. Players are investing heavily in R&D to develop novel pipeline drugs. Favorable regulatory environment and reimbursement policies will augment market access. Widespread vaccination drives and resumption of normal healthcare activities will further accelerate market growth in the coming years.
Europe holds the largest share of bullous pemphigoid market in terms of value owing to sizeable patient pool and high treatment uptake. North America follows Europe in terms of revenue generation led by rising disease prevalence and advanced healthcare infrastructure. Asia Pacific is recognized as the fastest growing regional market and will continue exhibiting strong growth momentum through 2031. This can be attributed to improving access to diagnosis and treatment options due to expanding healthcare expenditure in countries like China and India.
Geographical Regions With Highest Bullous Pemphigoid Market Value
North America accounts for the largest share of the Bullous Pemphigoid Market value-wise. The region is estimated to hold over 35% revenue share of the overall market in 2024 led by strong presence of leading pharmaceutical companies in US and Canada. Increased focus on research into novel treatment options along with supportive reimbursement policies are driving the growth of the North America bullous pemphigoid market.
Europe holds the second largest value share globally on account of rising burden of the autoimmune disorder due to aging population. Countries like Germany, UK, France, Italy are major revenue generators for Europe bullous pemphigoid market. High healthcare expenditure and availability of affordable treatments make Europe an attractive regional market.
Geographical Region Witnessing Fastest Growth In Bullous Pemphigoid Market
Asia Pacific region has emerged as the fastest growing geographical market for bullous pemphigoid globally. The Asia Pacific bullous pemphigoid market is projected to expand at a CAGR of over 12% during 2024-2031. Factors such as growing geriatric demographic, increasing medical awareness regarding bullous pemphigoid diagnosis and management, rising healthcare spending, and improving access to advanced drugs are fueling the market growth. Countries like India, China, Japan, and South Korea are expected to drive substantial revenues for bullous pemphigoid treatment manufacturers within Asia Pacific market.
Get more insights on this topic: https://www.ukwebwire.com/bullous-pemphigoid-market-growth-to-be-fueled-by-advancements-in-targeted-therapies/
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
What Are The Key Data Covered In This Bullous Pemphigoid Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors
FAQ’s
Q.1 What are the main factors influencing the Bullous Pemphigoid Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment